Astria Therapeutics, Inc. Common Stock

ATXS

Astria Therapeutics, Inc. (ATXS) is a biotechnology company focused on developing treatments for rare autoimmune and allergic diseases. The company specializes in innovative therapies aimed at addressing unmet medical needs, particularly in the fields of immunology and inflammation.

$13.01 +0.04 (0.31%)
Payout Frequency

Dividend History

Pay DateAmountEx-DateRecord Date
February 28, 2005$0.402005-03-292004-12-31
February 28, 2004$0.362004-03-182003-12-31

Dividends Summary

Company News

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights
GlobeNewswire Inc. • Halper Sadeh Llc • November 22, 2025

Law firm investigating potential securities law violations and fiduciary duty breaches for multiple companies involving merger and acquisition transactions.

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'
Benzinga • Vandana Singh • October 14, 2025

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics for $700 million, adding a new product candidate (Navenibart) for hereditary angioedema treatment, with the deal expected to close in Q1 2026.

Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research • Zacks Equity Research • March 12, 2024

Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.

Related Companies